Vitamin gummies recalled due to undeclared peanut allergen: Which products are affected?
'Vita Warehouse Corp. is voluntarily recalling one lot of Welby® brand Vitamin B12 Energy Support gummy product 1000 mcg 140 gummies, Berkely Jensen® Vitamin B12 1000 mcg 250 Gummies, and VitaGlobe™ Vitamin B12 Extra Strength 60 Gummies due to the potential presence of undeclared peanuts. People with an allergy or severe sensitivity to peanuts run the potential risk of serious or life-threatening allergic reactions if they consume these products. These products were distributed at ALDI and BJ's retail stores nationwide and online,' the statement read.
Affected products carry the following packaging particulars:
Aldi Welby®: Clear bottle with white cap, using green, red, and white labeling.
UPC Code: 4099100290868
Lot #: 248046601*
Expiration Date: 10/2026*
Berkley Jensen®: Clear bottle with white cap, using red and pink labeling.
UPC Code: 888670132487
Lot #: 248046601*
Expiration Date: 10/2026*
VitaGlobe: Clear bottle with white cap, using white and red labeling.
UPC Code: 850005214670
Lot #: 248046601*
Expiration Date: 10/2026*
Lot code and expiration date are printed on the bottom of the bottle.
All people who might have purchased this product in the given time frame are required to either claim a full refund at the place of purchase or dispose of the product immediately to avoid any life-threatening medical concerns. If any consumer shows signs of anaphylactic shock, they are advised to call 911 immediately. As of now, no injuries or illnesses have been reported due to the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
11 hours ago
- Indian Express
Bhiwandi Darbar follows Cafe Goodluck: FDA suspends licence of another popular Pune restaurant
After Cafe Goodluck, it is now the turn of Bhiwandi Darbar in Pune's Camp, where the Food and Drug Administration (FDA) has taken a stern view of the unhygienic conditions and suspended the restaurant's licence. Suresh Annapure, FDA Joint Commissioner, Pune division, told The Indian Express that the licence was suspended following an inspection of the restaurant. A complaint was filed with the Cantonment police almost a month ago by a woman who allegedly found a cockroach in her soup at Bhiwandi Darbar. The police collected the food sample and sent it to the FDA. 'Our inspection has been completed. There are unhygienic conditions at the restaurant, and we have suspended the licence of Bhiwandi Darbar,' Annapure said. The restaurant has been directed to stop operations until it complies with food safety regulations. 'We have identified several issues where the restaurant has not followed rules, and they are mainly related to unhygienic conditions,' Annapure added. This action comes close on the heels of the suspension of the licence of Pune's popular eatery Cafe Goodluck at Deccan Gymkhana. There, too, the action of suspending the licence of one of the oldest restaurants was taken after a video purportedly showing glass pieces in a bun at the food joint went viral on social media. The FDA conducted an inspection and identified several concerns related to hygiene. 'We will again carry out our inspection after these restaurants – Cafe Goodluck or Bhiwandi Darbar are able to comply with the regulations,' Annapure said. The FDA joint commissioner, when asked about inspections and actions on other outlets of these restaurants in the city, said that they had not received any other complaints from other branches. 'However, we have appealed to citizens to be vigilant and ensure that the Food Safety and Standards Authority of India (FSSAI) licence is prominently displayed at the hotel premises. This is a mandatory requirement for all food businesses, including restaurants, to ensure food safety and hygiene,' Annapure said. 'We are also encouraging citizens to ensure they take the food bill at the hotel. So if there is any discrepancy, then it will be easy to complain based on the bill,' he added. In a relief of sorts for the FDA Pune division, which includes the districts of Pune, Satara, Sangli, Kolhapur, and Solapur, the staff shortage issue is being addressed. Currently, the Pune district has 15 food safety officers. However, vacant posts are being filled, and 21 new food safety officers will soon join the existing staff. Overall, there are 47 posts of food safety officers in the Pune district, and measures have been taken to address the shortage, which had affected the regularity of inspection drives. Street food hubs are designated spaces where vendors operate under hygienic conditions and safety standards that are certified by the FSSAI, This is as part of the 'Eat Right and Clean Street Food Hub' initiative. The FSSAI also uses a hygiene rating system for street food hubs, which is visually depicted by smileys on certificates. 'The more the number of smileys clearly provides consumers to easily understand the hygiene levels,' Annapure said, adding that the audit of the Sarasbaug street food hub has given this food space a clean chit. The FSSAI has appointed private agencies to conduct the audit, and other street food hubs will also be assessed. The aim is to strengthen food safety surveillance and also encourage self-compliance, officials added.
Time of India
12 hours ago
- Time of India
West Virginia ban on abortion medication upheld
A divided federal appeals court on Tuesday upheld West Virginia's near-total ban on abortion, including limits on the widely used medication abortion drug mifepristone. The 4th U.S. Circuit Court of Appeals in Richmond, Virginia, said the Food and Drug Administration's approval of mifepristone did not preempt West Virginia's law as applied to medication abortions, which account for more than half of U.S. abortions. Circuit Judge J. Harvie Wilkinson said a 2007 federal law giving the FDA more authority over "high-risk" drugs did not evince a clear intention to displace states' traditional right to protect their citizens' health and safety. Wilkinson also found no indication that Congress intended to guarantee nationwide access to mifepristone. "The debate joined by able and dedicated supporters and opponents of access to abortion medications is simply not one, in the absence of clear congressional direction, for this court to decide," the judge wrote. Tuesday's 2-1 decision is the first by a federal appeals court to say states can restrict use of the pill. In June 2024, the U.S. Supreme Court preserved access to mifepristone, rejecting an effort by anti-abortion doctors and groups to roll back FDA approval. West Virginia's law had been challenged by GenBioPro, a Nevada company that sells a generic version of mifepristone. Opponents said letting the law stand could allow other states to criminalize access to federally approved medications. The law "sets a dangerous precedent regarding access to other evidence-based health care that (the) FDA has deemed safe and effective," said Skye Perryman, president of the nonprofit Democracy Forward, which helped represent GenBioPro. Erin Hawley, a lawyer representing West Virginia, said the court "rightly refused GenBioPro's invitation to federalize the issue of abortion." Hawley is senior counsel at the nonprofit Alliance Defending Freedom, which also brought the Supreme Court mifepristone case. Governor Patrick Morrisey , a Republican who defended West Virginia's law as that state's attorney general, called the decision a "big win" that lets West Virginia "lead the nation in our efforts to protect life." DISREGARDING SUPREME COURT 'NOT AN OPTION' Mifepristone is the first pill, followed by the drug misoprostol, for medication abortion in the first 10 weeks of pregnancy, and won FDA approval in 2000. Twenty-eight states restrict access to medication abortions, according to the nonprofit Guttmacher Institute, which focuses on reproductive health. West Virginia's Unborn Child Protection Act banned abortion with narrow exceptions, including within the first 14 weeks of pregnancy for minors who are victims of rape and incest. Without opining on the law, Wilkinson said federal courts shouldn't substitute their policy preferences for those of state legislators. He also said voiding the law would amount to near "defiance" of Dobbs v. Jackson Women's Health Organization , the 2022 Supreme Court decision that eliminated the federal constitutional right to abortion. "Just after the Supreme Court restored the states' traditional authority to regulate abortion, GenBioPro would have us wrest it right back," Wilkinson wrote. "At a time when the rule of law is under blunt assault, disregarding the Supreme Court is not an option," he added. Wilkinson was appointed to the bench by Republican President Ronald Reagan. His opinion was joined by U.S. District Judge Rossie Alston, an appointee of Republican President Donald Trump who normally sits in Alexandria, Virginia. Circuit Judge DeAndrea Gist Benjamin, an appointee of Democratic President Joe Biden, dissented, saying West Virginia's law "erects barriers to life-saving healthcare for countless West Virginians in ways not envisioned by Congress." She also said the law could unduly burden patients in medically underserved areas elsewhere by forcing West Virginians to travel to other states for treatment. Tuesday's decision upheld an August 2023 ruling by U.S. District Judge Robert Chambers in Huntington, West Virginia.
&w=3840&q=100)
Business Standard
12 hours ago
- Business Standard
Biocon Biologics expands diabetes portfolio with FDA approval for Kirsty
Biocon Biologics, a subsidiary of biopharmaceutical company Biocon, said on Wednesday that the US Food and Drug Administration (FDA) has approved Kirsty (Insulin Aspart), the 'first and only' interchangeable biosimilar to NovoLog (Insulin Aspart). Kirsty is a rapid-acting human insulin for improving glycaemic control in adults and paediatric patients with diabetes mellitus. It will be available as a single-patient-use prefilled pen for subcutaneous administration and as a multi-dose vial for both subcutaneous and intravenous use. (An interchangeable biosimilar can be swapped for its original biologic at the pharmacy without prescriber approval.) 'The FDA approval of Kirsty, the first and only interchangeable biosimilar rapid-acting Insulin Aspart in the US, is a significant step forward in our efforts to make insulin more accessible and affordable,' said Shreehas Tambe, chief executive officer and managing director of Biocon Biologics. 'It builds on the foundation we laid with Semglee, reinforcing our commitment to scientific excellence and patient-centric innovation. With Kirsty, we are expanding treatment choices for people living with diabetes and advancing our ambition to be a global leader in addressing unmet needs in diabetes care,' he said. The approval for Kirsty strengthens Biocon Biologics' biosimilar insulin portfolio, which includes Semglee Insulin, the first FDA-approved interchangeable biosimilar. Kirsty has been available in Europe and Canada since 2022. Biocon Biologics in March announced a strategic collaboration with Civica Inc. to improve access and affordability of Insulin Aspart in the US. The company has also previously received US FDA approvals for biosimilars, including Ogivri (biosimilar Trastuzumab), Fulphila (Pegfilgrastim), and Semglee (Insulin Glargine).
